Moritz Hillgenberg

• Commercial Opportunity Assessment & Market Research
• Licensing & Due Diligence Support
• Start-Up Consulting

Dr. Moritz Hillgenberg, the founder of Hillgenberg Pharma Biotech Consulting, has has a wide range of experience in the life sciences gained in over 15 years working in academic research, biotechnology R&D, pharmaceutical drug development, and consulting. He has a dual qualification in life sciences and economics holding a PhD in Molecular Biology from Humboldt-University Berlin, and an MBA from the Institute of Management Berlin, and combines on-hand experience in research and drug development with sound understanding of healthcare markets.

Since 2007, Dr. Hillgenberg provides independent consultancy services, delivering in-depth understanding of the commercial potential of products as a basis for strategic decision-making. Since 2008, he is also a core team member of groupH, a UK-based international healthcare consulting firm (www.grouph.co.uk ). He also recently started “clinvaluate”, a multidisciplinary combined clinical-commercial evaluation service offered together with Schott Consulting in Clinical Research (www.clinvaluate.com). Over the last 5 years, a large variety of projects have been executed for small or medium Biotech and Medtech companies as well as global Pharma companies in EU, US, and Asia.

Before entering the consulting field, he served as Chief Operations Officer at OSSOGEN Biopharm GmbH and BiRDS Pharma GmbH (both Berolina Drug Development Group), where he headed the development activities for the several drug development projects (including Biologics, NCEs, and Generics). Before that, he held positions as Scientific Director of Custos Biotechnologie GmbH and as project leader in the gene therapy program at HepaVec AG and Develogen AG. He started is career as academic researcher at Max Delbrück Center for Molecular Medicine (MDC) and the German Cancer Research Center (DKFZ), and is author of 10 research papers and 5 international patent families.

Dr. Hillgenberg is co-founder of Conelis e.V. and served as first vice chairman of its board.

Dual qualification in life sciences and economics combined with wide range of experience gained in over fifteen years working in academic research, biotechnology R&D, and pharmaceutical drug development.

Education:

Biologist (Dipl.-Biol.)
PhD (Dr. rer. nat.)
Master of Business Administration (M.B.A.)

Experience:

Consulting activities:

Head of Hillgenberg Pharma Biotech Consulting, focus on commercial assessment (since 2007)
Core team member of groupH, a UK-based international consulting firm (since 2008)
Offering combined commercial-clinical evaluation with partner Schott Consulting in Clinical Research (since 2009)

Leading positions before starting consulting activities:

Chief Operations Officer at OSSOGEN Biopharm GmbH
Chief Operations Officer at BiRDS Pharma GmbH
Scientific Director at Custos Biotechnologie GmbH

Prior active research in industry and academia:

Project leader at HepaVec AG and DeveloGen AG
Academic research at Max Delbrück Center for Molecular Medicine (MDC) and German Cancer Research Center (DKFZ)

Areas of Expertise:

Commercial Assessment, Market Research

Typical assignments have been (incl. also collaborative projects with groupH and Schott Consulting in Clinical Research):

Evaluation of global opportunities for new antivirals across multiple indications and assets potentially available for in-licensing (global Pharma company)

Analysis of existing and upcoming targeted therapy competition and clinical development trends in lung cancer (global Pharma company)

Assessment of development plan and commercial opportunity for a new patented application of targeted therapies for cardiovascular disease (German funding organization)

Combined commercial- clinical evaluation of a candidate for hematopoietic stem cell mobilization in early clinical development (mid-sized European Biotech company)

Development of a pricing and reimbursement strategy for a new device for isolated organ perfusion for treating cancer (small European Medtech company)

Commercial evaluation of current use and potential clinical development of a local treatment for a male sexual dysfunction (global Pharma company)

Commercial evaluation and sales forecast of new radiosensitizing nanoparticles for treatment of cancer (small European Medtech company)

Commercial evaluation and sales forecasts of a new device for isolated organ perfusion for treating cancer (small European Medtech company)

Commercial evaluation of an in-licensing opportunity for treatment of diabetes (global Pharma company)

Development of a global market model for 8 major ophtalmologic indications, including epidemiology, diagnosis rates and treatment rates to allow for evaluation of new development candidates (mid-sized European Biopharma company)

Combined commercial- clinical evaluation of a candidate for the inhibition of a new cellular target in preclinical development (mid-sized European Biotech company)

Commercial evaluation of preclinical candidates for cardiovascular conditions, incl. aortic aneurism and pulmonary hypertension (global Pharma company)

Commercial evaluation on global forecast for a new agent in clinical development for for treatment of diabetes (global Pharma company)

Development of a global dynamic model of the diabetes market to generate commercial forecasts for multiple compounds in development, incl. consensus-building with national marketing organizations and cross-functional teams (global Pharma company)

Commercial evaluation of a preclinical pipeline candidate for treating or preventing menstrual bleeding disorders (global Pharma company)

Evaluation of the attractiveness of the antiinfectives market, including tropical diseases, infections in transplant recipients, and influenza (global Pharma company)

Market research focusing on physicians interviews to support the development of a dermatology disease area strategy (global Pharma company)

Market research focusing on identification, selection, and interviewing potential customers to support development of market entry strategy (US-based formulation service provider)

Evaluation of the competitive and regulatory landscape for a biological with potential benefit in women´s health, including also strategic development recommendations (small European-Asian joint venture)

Evaluation of the EU and US market for a medical device in the area of gynecology, positioning of product, and market entry strategy (small European Medtech company)

Evaluation of patent, development and market related aspects of candidates for use in an innovative drug development technology platform, incl. pipeline focus recommendations (US start-up company)